AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
AAPL   317.94 (-0.10%)
MSFT   183.25 (+1.02%)
FB   225.09 (-0.16%)
GOOGL   1,433.52 (+1.08%)
AMZN   2,442.37 (+1.72%)
NVDA   355.02 (+4.58%)
CGC   17.37 (-20.03%)
BABA   207.39 (+3.96%)
MU   47.91 (+3.10%)
GE   6.57 (-3.10%)
TSLA   835.00 (+3.62%)
AMD   53.80 (+3.98%)
T   30.86 (-0.64%)
ACB   14.08 (-8.21%)
F   5.71 (-2.39%)
GILD   77.83 (+3.33%)
DIS   117.30 (+0.47%)
NFLX   419.73 (+1.52%)
BAC   24.12 (-2.98%)
BA   145.85 (-2.65%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 DelMar PharmaceuticalsX T L BiopharmaceuticalsiCo TherapeuticsANCHIANO THERAP/SCapricor Therapeutics
SymbolNASDAQ:DMPINASDAQ:XTLBOTCMKTS:ICOTFNASDAQ:ANCNNASDAQ:CAPR
Price Information
Current Price$1.03$1.37$0.04$1.10$4.64
52 Week RangeBuyN/AN/AHoldBuy
Beat the Market™ Rank
Overall Score1.30.60.51.21.3
Analysis Score3.50.00.03.03.5
Community Score2.42.82.62.52.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.60.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyN/AN/AHoldBuy
Consensus Price Target$2.00N/AN/A$16.00$10.50
% Upside from Price Target94.17% upsideN/AN/A1,354.55% upside126.29% upside
Trade Information
Market Cap$11.77 million$7.45 million$4.57 million$7.79 million$65.17 million
Beta1.430.862.890.877.08
Average Volume281,3097,39652,09035,8053,800,552
Sales & Book Value
Annual RevenueN/AN/AN/AN/A$1 million
Price / SalesN/AN/AN/AN/A66.18
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($0.09) per share$1.36 per share($0.01) per share$1.56 per share$0.67 per share
Price / BookN/AN/AN/AN/A6.93
Profitability
Net Income$-8,050,000.00$-1,350,000.00$-1,450,000.00$-27,120,000.00$-7,640,000.00
EPS($3.16)N/AN/A($3.46)($2.06)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/A-750.83%
Return on Equity (ROE)N/A-14.72%-449.33%-54.04%-128.89%
Return on Assets (ROA)-131.37%-14.38%-183.51%-33.83%-70.97%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.01%N/A
Current Ratio3.69%29.44%4.37%4.23%10.39%
Quick Ratio3.69%29.44%4.37%4.23%10.39%
Ownership Information
Institutional Ownership Percentage1.94%8.52%N/A7.49%3.50%
Insider Ownership Percentage7.70%N/AN/A6.88%8.60%
Miscellaneous
Employees4N/AN/A19N/A
Shares Outstanding11.43 million5.14 million153.75 million7.42 million14.26 million
Next Earnings Date9/8/2020 (Estimated)9/2/2020 (Estimated)6/4/2020 (Estimated)8/3/2020 (Estimated)8/4/2020 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.